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Introduction
Treatments inhibiting the enzymatic activity of mutated BRAF 
protein, a serine- threonine protein kinase, in patients with 
advanced or metastatic melanoma (MM) became available 
in 2010 and have demonstrated improved progression- free 
survival (PFS) and overall survival (OS) for patients with 
BRAF-mutated melanoma [1, 2]. BRAF mutations are present 
in 50% of patients with advanced melanoma [3–5]. Trametinib 
is a mitogen- activated protein kinase/extracellular 
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Abstract
Trametinib, a selective inhibitor of mitogen- activated protein kinase kinase 1 
(MEK1) and MEK2, significantly improves progression- free survival compared 
with chemotherapy in patients with BRAF V600E/K mutation–positive advanced 
or metastatic melanoma (MM). However, the pivotal clinical trial permitted 
randomized chemotherapy control group patients to switch to trametinib after 
disease progression, which confounded estimates of the overall survival (OS) 
advantage of trametinib. Our purpose was to estimate the switching- adjusted 
treatment effect of trametinib for OS and assess the suitability of each adjust-
ment method in the primary efficacy population. Of the patients randomized 
to chemotherapy, 67.4% switched to trametinib. We applied the rank- preserving 
structural failure time model, inverse probability of censoring weights, and a 
two- stage accelerated failure time model to obtain estimates of the relative treat-
ment effect adjusted for switching. The intent- to- treat (ITT) analysis estimated 
a 28% reduction in the hazard of death with trametinib treatment (hazard ratio 
[HR], 0.72; 95% CI, 0.52–0.98) for patients in the primary efficacy population 
(data cut May 20, 2013). Adjustment analyses deemed plausible provided OS 
HR point estimates ranging from 0.48 to 0.53. Similar reductions in the HR 
were estimated for the first- line metastatic subgroup. Treatment with trametinib, 
compared with chemotherapy, significantly reduced the risk of death and risk 
of disease progression in patients with BRAF V600E/K mutation–positive  advanced 
melanoma or MM. Adjusting for switching resulted in lower HRs than those 
obtained from standard ITT analyses. However, CI are wide and results are 
sensitive to the assumptions associated with each adjustment method.
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signal–regulated kinase kinase (MEK) inhibitor that was 
approved in May 2013 in the United States.
METRIC (MEK Versus Dacarbazine [DTIC] or Paclitaxel 
[Taxol] in Metastatic Melanoma) was a randomized, mul-
ticenter phase 3 trial evaluating the efficacy and safety of 
trametinib compared with standard chemotherapy 
 (dacarbazine or paclitaxel) in patients with advanced or 
metastatic (stage IIIc or IV) BRAF V600E/K mutation–posi-
tive melanoma. The prespecified number of PFS events was 
reached in October 2011. An intent- to- treat (ITT) analysis 
(comparing groups as randomized, without adjustment for 
treatment switching), conducted in February 2012, estimated 
a 58% reduction in the hazard for progression with trametinib 
(hazard ratio [HR], 0.42; 95% CI, 0.29–0.59) [2]. The HR 
for death was 0.54 (95% CI, 0.32–0.92), but median OS 
had not been reached. In addition, the trial protocol allowed 
patients randomized to the chemotherapy control group 
who had progressive disease (PD) to switch onto trametinib 
and 51 patients (47.2%) had done so. Following this analysis, 
a protocol amendment dictated that immediate switching 
was permitted in patients randomized to the control group.
When treatment switching is permitted, an ITT analysis 
can be confounded. If switching is permitted after PD, 
postprogression survival (PPS) in switching patients is likely 
to be extended compared with the PPS that would have 
been observed in the absence of switching. Therefore, an 
ITT analysis is likely to underestimate the OS effect of a 
novel treatment (Fig. 1) [6, 7]. Accurate estimates of OS 
are important for patients, clinicians, and regulators, but 
are particularly crucial for health technology assessment 
because a lifetime horizon is generally taken in economic 
evaluations of interventions that affect survival [6, 8–11]. 
Inaccurate estimates of the OS advantage of a new treat-
ment will result in inaccurate cost- effectiveness results, 
possibly leading to inappropriate reimbursement decisions. 
This has serious implications for patients because access 
to effective treatments may be denied. The result is likely 
to be lost lives, lost quality of life, and an inefficient allo-
cation of scarce healthcare budgets [12].
Statistical methods that adjust for treatment switching 
are available. However, naive “per- protocol” methods that 
simply exclude switchers from the analysis, or censor 
them at the time of switch, will produce biased results 
because the propensity to switch is likely to be correlated 
with patient prognosis [6, 7, 13]. Thus, more complex 
methods are required to improve upon the ITT analysis 
and account for treatment switching. Rank- preserving 
structural failure time models (RPSFTM) and inverse 
probability of censoring weights (IPCW) are well- 
established methods that may be used for this purpose 
[7, 14–18]. A simplified two- stage method for adjusting 
for treatment switching has been recently suggested [6].
In this study, we apply RPSFTM, IPCW, and two- stage 
methods to account for confounding associated with treat-
ment switching in METRIC to obtain a more reliable 
estimate of the true OS treatment effect of trametinib 
compared with chemotherapy, using a May 2013 data 
cut. In line with recent methodological recommendations 
[6], we assessed the suitability of each adjustment method 
in the context of METRIC.
Materials and Methods
Patients
Patients enrolled on METRIC were randomized 2:1 to receive 
trametinib 2 mg once daily or chemotherapy (dacarbazine 
or paclitaxel). A total of 322 patients were enrolled on the 
study (Fig. 2). Patients were permitted to have previously 
received 1 line of chemotherapy treatment for advanced 
myeloma or MM. We conducted analyses for two groups: 
the primary efficacy population, including patients with 
Figure 1. Treatment switching bias. OS, overall survival; PFS, progression- free survival; PPS, postprogression survival; RCT, randomized controlled trial. 
(Reproduced with permission from Latimer et al. [6] .
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BRAF V600E–positive MM with no history of brain metas-
tases, and the subgroup within this population who received 
no previous treatment for advanced myeloma or MM. We 
focused on the primary efficacy population because an 
amendment to the METRIC trial protocol was made that 
dictated that the primary efficacy analysis was restricted to 
patients with the BRAF V600E mutation who did not have 
brain metastases, based upon data from the phase 2 study 
of trametinib, which indicated improved effectiveness in this 
group [2, 19]. There were 273 patients in the primary effi-
cacy population (trametinib, n = 178; chemotherapy, n = 95) 
and 176 patients in the first- line metastatic subgroup 
(trametinib, n = 114; chemotherapy, n = 62). Further details 
of the study design are provided elsewhere [2, 20]. The 
study cutoff date for this analysis of OS was May 20, 2013.
Ethics
The study was approved by the institutional review board, 
and all patients provided written, informed consent to 
participate in the study.
Statistical analyses
The RPSFTM estimates counterfactual survival times (i.e., 
survival times that would have been observed in the absence 
of treatment switching) [14]. We fitted a Cox proportional 
hazards model (stratified for lactate dehydrogenase [LDH] 
level and prior chemotherapy for advanced or metastatic 
disease) to observed trametinib group survival times and 
counterfactual chemotherapy group survival times and esti-
mated what the HR treatment effect would have been if 
switching had not occurred. The one- parameter RPSFTM 
relies on the assumptions that the treatment effect is equal 
across all patients, relative to the duration of time the treat-
ment was taken for (the “common treatment effect” assump-
tion), and, in the absence of treatment, that survival times 
are independent of the randomized group (the “randomiza-
tion” assumption). We assessed the performance of the 
RPSFTM by comparing counterfactual survival times esti-
mated for the control group with those estimated for the 
experimental group (i.e., survival times that would have been 
observed if no patients in either group received treatment). 
If this provides an HR close to 1, this signals that the model’s 
estimation procedure has performed well. However, this does 
not mean that the assumptions associated with the method 
are justified, or that the data fit the model. To provide a 
further check on the suitability of the RPSFTM we visually 
compared the complete counterfactual survival curves. We 
also used the switching- specific treatment effect obtained 
from the two- stage estimation method (described below) to 
assess the plausibility of the common treatment effect 
assumption.
The Iterative Parametric Estimation (IPE) adjustment 
method adapts the RPSFTM by using a parametric esti-
mation procedure [21]. We applied the IPE method in 
this case study, but found that due to convergence issues 
(i.e., treatment effects not being identified by the iterative 
estimation procedure) it was consistently outperformed 
by the RPSFTM. Therefore, we do not report on this 
method further.
The IPCW method artificially censors patients at the 
point of treatment switch and estimates weights for the 
observations associated with remaining patients according 
to their baseline and time- varying demographic and disease- 
related characteristics to adjust for any potential confound-
ing created by the artificial censoring [15, 22]. These 
weights are then used in a weighted Cox proportional 
Figure 2. METRIC study design. FPFV, first patient, first visit; ITT, intent- to- treat; LDH, lactate dehydrogenase; LPLV, last patient, last visit; OS, overall 
survival; PCR, polymerase chain reaction; PEP, primary efficacy population; PFS, progression- free survival; QD, once daily; RGI, Response Genetics, Inc; 
RR, response rate; ULN, upper limit of normal.
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hazards regression model to obtain an adjusted estimate 
of the treatment effect [15, 22]. The method is reliant 
on the assumption that the model includes information 
on all prognostic characteristics (the “no unmeasured 
confounders” assumption). To address the validity of our 
IPCW analysis, we considered the plausibility of the no 
unmeasured confounders assumption given the data col-
lected in METRIC.
The two- stage estimation method can be applied when 
switching occurs after a disease- related time point [6]. 
For METRIC, we used the PD time point as a secondary 
baseline for all control group patients and compared PPS 
in control group switchers and nonswitchers using an 
accelerated failure time model, adjusting for prognostic 
characteristics measured at baseline and PD. We used the 
acceleration factor (AF) obtained from this model to adjust 
survival times observed in switching patients to obtain 
counterfactual survival times. We then fitted a Cox pro-
portional hazards regression model (stratified for LDH 
level and prior chemotherapy for advanced or metastatic 
disease) to the observed trametinib group survival times 
and the counterfactual chemotherapy group survival times 
to estimate a treatment switching- adjusted HR. This method 
is theoretically inferior to the IPCW method if switching 
does not occur immediately upon PD because it does 
not adjust for time- dependent confounding that may occur 
between PD and switching. However, it has been shown 
to be less prone to convergence issues and bias than the 
IPCW method in scenarios when sample sizes are small 
and switching proportions are high, and, unlike the 
RPSFTM method, does not make the common treatment 
effect assumption [6, 23, 24]. To assess the validity of 
the two- stage analysis, we examined the time between 
PD and switching to investigate potential bias from time- 
dependent confounding.
Censoring in counterfactual datasets can be problematic 
because the treatment received affects the probability that 
the survival time of an individual is censored by the 
study end date [23]. Possible bias from this can be avoided 
by breaking the dependence between censoring time and 
treatment by “recensoring” at an earlier time point based 
upon the observed administrative censoring time and the 
size of the treatment effect [25, 26]. A drawback to 
recensoring is that it involves “throwing away” informa-
tion; if the treatment effect changes over time, recensoring 
will lead to a biased estimate of the average treatment 
effect because longer term data are discarded. To address 
this, we conducted our RPSFTM and two- stage analyses 
with and without recensoring.
We used Stata version 13.1 software [27] to carry out all 
of our analyses, and we used the strbee command to apply 
the RPSFTM method [28]. Further details on the imple-
mentation of each method, including information on baseline 
and time- dependent characteristics incorporated within the 
IPCW and two- stage analyses, are presented in the Data S1.
Results
In the primary efficacy population, 64 patients (67.4%) 
in the control group had switched to trametinib at the 
time of data cutoff. Of these, 62 patients switched after 
disease progression had occurred – hence, we deemed 
it unnecessary to attempt to adjust for the effect of 
switching on estimates of the treatment effect on PFS, 
but it is clear that control group OS is likely to be 
confounded. There were 109 deaths (61.2%) in the 
Figure 3. Time to switch from progression for patients on the chemotherapy control arm of the METRIC study who switched to trametinib treatment.
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trametinib group and 61 (64.2%) in the control group 
(42 switchers and 19 nonswitchers). Figure 3 presents 
the time from PD until switch in switching patients. 
Approximately 75% of switching occurred fewer than 
40 days after PD, with a median time from progression 
until switching of 23 days.
The ITT analysis for the primary efficacy population 
showed that OS was improved for patients randomized to 
trametinib compared to those randomized to chemotherapy 
(HR from a Cox proportional hazards regression model 
stratified for LDH level and prior chemotherapy for advanced 
or metastatic disease, 0.72; 95% CI, 0.52–0.98).
The results of the adjustment analyses are presented 
in Table 1, and Figure 4 and Figure 5 illustrate Kaplan–
Meier curves representing observed survival times for the 
trametinib group and counterfactual survival times esti-
mated for the chemotherapy group by the RPSFTM and 
two- stage adjustment methods. The analyses that adjusted 
for treatment switching resulted in reduced HRs and a 
larger divergence between Kaplan–Meier curves for the 
trametinib and chemotherapy groups. The RPSFTM 
method produced an OS HR of 0.38 (95% CI, 0.15–0.95) 
when recensoring was incorporated and 0.49 (95% CI, 
0.25–0.96) when recensoring was not undertaken. The 
IPCW estimate of the OS HR was 0.48 (95% CI, 0.25–0.91), 
and the two- stage method provided an OS HR of 0.43 
(95% CI, 0.20–0.96) when recensoring was incorporated 
and 0.53 (95% CI, 0.29–0.97) when recensoring was not 
undertaken (Table 1).
The first- line metastatic subgroup included 176 patients 
(trametinib, n = 114; chemotherapy, n = 62). In this 
subgroup, 43 patients on chemotherapy (69.4%) switched 
to trametinib. There were 70 deaths (61.4%) in the 
trametinib group and 40 (64.5%) in the chemotherapy 
group (29 switchers and 11 nonswitchers). The first- line 
subgroup ITT analysis indicated that the treatment benefit 
of trametinib compared with chemotherapy was slightly 
greater than that for the entire primary efficacy popula-
tion (HR from a Cox proportional hazards regression 
model stratified for LDH level, 0.67; 95% CI, 0.45–1.00), 
although the difference was not statistically significant. 
Switching adjustment methods again produced reduced 
HRs and a larger divergence between the Kaplan–Meier 
curves for the trametinib and chemotherapy groups 
(Fig. 5). The RPSFTM method produced an OS HR of 
0.33 (95% CI, 0.11–1.00) when recensoring was incorpo-
rated and 0.44 (95% CI, 0.20–1.00) when recensoring 
was not undertaken. The IPCW estimate of the OS HR 
was 0.33 (95% CI, 0.16–0.68). The two- stage method 
provided an OS HR of 0.51 (95% CI, 0.26–1.00) when 
recensoring was incorporated and 0.55 (95% CI, 0.30–1.00) 
when recensoring was not undertaken (Table 1).
Table 1. RPSFTM, IPCW and two- stage estimates of overall survival treatment effect.
Description
HR
CF HR 
comparison1
Median 
(chemo 
group, days)Point estimate Lower 95% CI Upper 95% CI
METRIC primary efficacy population
 ITT analysis 0.72 0.52 0.98 – 338.0
 RPSFTM 0.38 0.15 0.95 1.00 220.0
 RPSFTM without recensoring 0.49 0.25 0.96 1.00 220.0
 IPCW2 0.48 0.25 0.91 – –
 Two- stage method 0.43 0.20 0.96 – 244.2
 Two- stage method without recensoring 0.53 0.29 0.97 – 244.2
METRIC first- line metastatic primary efficacy population
 ITT analysis 0.67 0.45 1.00 – 338.0
 RPSFTM 0.33 0.11 1.00 1.00 196.0
 RPSFTM without recensoring 0.44 0.20 1.00 1.00 207.1
 IPCW2 0.33 0.16 0.68 – –
 Two- stage method2 0.51 0.26 1.00 – 256.5
 Two- stage method without recensoring2 0.55 0.30 1.00 – 268.5
CI, confidence interval; HR, hazard ratio; IPCW, inverse probability of censoring weights; ITT, intent- to- treat population; LDH, lactate dehydrogenase; 
OS, overall survival; RPSFTM, rank- preserving structural failure time models.
The ITT HRs presented in the table are estimated using Cox PH models, stratified for LDH. GSK use a Pike estimator to calculate ITT HRs. This resulted 
in a HR of 0.72 (95% CI, 0.52–1.01) for the Primary Efficacy Population and a HR of 0.74 (95% CI, 0.49–1.12) for the first- line metastatic subpopula-
tion. Results are given to 2 decimal places.
1CF HR comparison represents the comparison of counterfactual survival times in each randomized group if no patients in either group received any 
treatment, given the treatment effect estimated by the method. Successful estimation would result in a CF HR of 1.00.
2Analyses did not fully converge when all covariates were included. Results presented represent those from most complete application that converged 
(see Data S1. for full details).
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Discussion
Trametinib was previously shown to improve PFS and 
OS compared with chemotherapy in patients with BRAF 
V600E/K–mutant melanoma [2]. In the updated ITT 
analysis using the May 2013 data cut, the OS treatment 
effect was reduced and of borderline statistical significance, 
potentially due to the confounding effects of switching.
After adjustment for treatment switching, trametinib 
reduced the risk of death compared with chemotherapy, 
with HRs substantially lower than those from the ITT 
analysis, which estimated a 28% reduction in the hazard 
of death with trametinib. The most plausible RPSFTM, 
IPCW, and two- stage method analyses estimated reduc-
tions of between 47% and 52%. CI were wide and of 
borderline statistical significance, largely due to the design 
of the adjustment methods. The RPSFTM and two- stage 
methods retained the P value from the ITT analysis by 
design (though bootstrapping could alternatively be under-
taken), thus, in situations when the point estimate of the 
HR is reduced, CI widen. The IPCW analysis does not 
retain the ITT analysis P value (P = 0.04 in the ITT 
analysis reduced to P = 0.02 in the IPCW analysis).
The point estimate reductions in the OS HR were not 
unexpected; the majority of patients randomized to the 
chemotherapy group switched to trametinib (64 of 95 
patients [67.4%]). Given the large PFS treatment effect 
associated with trametinib, it is reasonable to expect that 
switching patients will live longer than they would have 
if they had not switched treatments. Adjusting for the 
treatment switching observed in the majority of chemo-
therapy group patients would therefore be expected to 
have a substantial impact on the estimate of the OS treat-
ment effect. Although adjustment methods such as the 
RPSFTM, IPCW, and two- stage estimation are likely to 
produce smaller bias than naive per- protocol adjustments 
[6, 7, 13], each method has important assumptions that 
must be considered.
The RPSFTM is reliant upon the common treatment 
effect assumption. This assumption may be implausible 
given that most switching patients received trametinib 
after PD, potentially resulting in a diminished capacity 
to benefit compared to patients who received trametinib 
immediately upon randomization. The comparison of 
counterfactual survival times estimated for the control 
group and the experimental group resulted in HRs of 
Figure 4. Overall survival in primary efficacy population. (A). Rank- preserving structural failure time models (RPSFTM) with recensoring. (B). RPSFTM 
without recensoring. (C). Two- stage method with recensoring. (D). Two- stage method without recensoring.
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1.00, suggesting that the RPSFTM analyses had worked 
well. However, a visual inspection of the counterfactual 
survival curves presented in Figure 4 A and B and Figure 5 
A and B suggests that the fit of the data to the model 
was not perfect, which may place some doubt on the 
validity of the common treatment effect assumption. 
Although the common treatment effect assumption is 
impossible to test with precision, the two- stage method 
provides an estimate of the postprogression treatment 
effect of trametinib specifically in switching patients com-
pared with patients who did not switch, and of the OS 
treatment effect of trametinib compared to chemotherapy 
adjusted for switching. If these estimated effects are similar, 
the common treatment effect assumption may be made 
more confidently, because it would appear that patients 
are receiving a similar benefit from the experimental treat-
ment no matter when they received it. For the primary 
efficacy population analysis, the two- stage method provided 
an estimate of the postprogression AF associated with 
switching to trametinib of 1.65 (95% CI, 1.11–2.45; an 
AF > 1 indicates a treatment that extends survival time). 
An OS AF of 1.75 was estimated for the trametinib group 
compared with the chemotherapy group, once adjustments 
had been made for switching. Hence, although the 
two- stage analysis is prone to some bias, there appeared 
to be no strong evidence against the common treatment 
effect assumption.
The IPCW is reliant on the no unmeasured confound-
ers assumption. Results are prone to substantial error with 
small sample sizes and large switching proportions [6, 
23]. The large amount of baseline and time- dependent 
data available on important prognostic variables collected 
during the METRIC trial lends itself to an IPCW analysis 
(see Data S1.for full details on prognostic factors included 
in the IPCW and two- stage analyses). However, the small 
sample size means that the IPCW results must be inter-
preted with caution: only 31 control group patients did 
not switch to trametinib, and these form the basis of the 
IPCW control group survival estimates. This is particularly 
relevant for the first- line subgroup analyses, for which 
the sample size is further reduced (only 19 control group 
patients did not switch). Indeed, weighting models did 
not successfully converge when all covariates were included 
bringing the feasibility of the no unmeasured confounders 
assumption into question. Health- related quality of life 
scores based upon the EuroQol 5D (EQ- 5D) were excluded 
from the primary efficacy population analysis, and 
European Organisation for Research and Treatment of 
Figure 5. Overall survival in first- line metastatic primary efficacy population. (A). Rank- preserving structural failure time models (RPSFTM) with 
recensoring. (B). RPSFTM without recensoring. (C). Two- stage method with recensoring. (D). Two- stage method without recensoring.
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Cancer quality of life 30 (EORTC QLQ- 30) domains were 
excluded from the first- line subgroup analysis (see Data 
S1. for further details). However, in each case the alterna-
tive quality of life measure was retained in the analysis 
(i.e., EQ- 5D was retained when EORTC QLQ- 30 was 
excluded, and vice- versa) and therefore these exclusions 
may not represent important violations of the no unmeas-
ured confounders assumption.
The two- stage estimation method is reliant upon the 
no unmeasured confounders assumption at PD and assumes 
that no additional time- dependent confounding occurs 
between PD and the time of treatment switch. For the 
primary efficacy population analysis, models converged 
that incorporated all covariates; therefore, the no unmeas-
ured confounders assumption is not unreasonable. 
However, in the first- line subgroup, EORTC QLQ- 30 
covariates were excluded for model convergence to be 
achieved; therefore, the results are less robust (although 
EQ- 5D covariates were retained, and hence the no unmeas-
ured confounders assumption may remain reasonable). 
Although Figure 3 suggests fairly rapid switching after 
PD (median 23 days), some patients took much longer 
to switch. Three patients switched more than 100 days 
after PD, leaving scope for additional time- dependent 
confounding to occur. Although the two- stage method 
cannot be expected to produce completely unbiased esti-
mates, remaining bias may be small because most switching 
happened soon after PD.
Recensoring was a key issue in our METRIC analysis. 
Whilst the issues around recensoring have been previously 
considered [6, 25, 29, 30], we are not aware of any pre-
vious analyses that have presented adjustment analysis 
results with and without incorporating recensoring. 
Figures 4 and 5 show that for the primary efficacy popu-
lation, recensoring led to a maximum survival time of 
422 days (14.1 months) for the RPSFTM and 498 days 
(16.6 months) for the two- stage method, compared with 
a maximum observed survival time of 792 days 
(26.4 months) in METRIC. It is noticeable that the largest 
gap between the observed trametinib and chemotherapy 
Kaplan–Meier curves occurs at approximately 400 days 
(13.0 months), after which the survival curves begin to 
converge. This may be partly due to switching. However, 
only 14 of the 64 switchers remained on trametinib after 
this time point; therefore, it seems likely that most of 
the impact of switching would already be apparent at 
422 days. Despite this, we found that artificially censoring 
all patients in both the chemotherapy and trametinib 
groups at 422 days resulted in an ITT HR of 0.56, com-
pared with the ITT HR of 0.72 at the end of follow- up. 
We hypothesize that at least part of the convergence of 
the survival curves after 422 days is associated with a 
reduction in the trametinib treatment effect over time; 
therefore, recensoring at early time points will lead to an 
overestimate of the true longer term average OS treatment 
effect. For this reason, we believe that RPSFTM and two- 
stage analyses without recensoring provide more credible 
results for the primary efficacy population. For the first- 
line subgroup, the impact of recensoring is different for 
the RPSFTM and two- stage analyses. For the RPSFTM, 
recensoring led to a maximum survival time of 392 days 
(12.9 months) compared to 611 days (20.1 months) for 
the two- stage analysis (Fig. 5). Hence the loss of informa-
tion associated with recensoring is much less pronounced 
for the two- stage analysis. Artificially censoring all patients 
at 611 days resulted in an ITT HR of 0.66 for the first- 
line subgroup, compared to 0.67 at the end of follow- up. 
Therefore, in the first- line subgroup our preference is for 
the RPSFTM analysis without recensoring and the two- 
stage analysis with recensoring.
These analyses that adjust for the switching observed 
in METRIC confirm that trametinib improved OS, com-
pared with chemotherapy, in patients with MM with a 
V600E/K BRAF mutation. The size of the treatment effect 
was considerably larger than that estimated using a stand-
ard, unadjusted ITT analysis. Although adjustment methods 
have important limitations, they are likely to provide a 
more reliable estimate of the true treatment effect of 
trametinib than an ITT analysis. Given the particular 
characteristics of METRIC, the RPSFTM, and two- stage 
methods that do not incorporate recensoring may be more 
appropriate than those that do. A key advantage of the 
two- stage and IPCW analyses is that they do not require 
the common treatment effect assumption, although this 
assumption appears reasonable in this case. Two- stage 
analyses are potentially more prone to bias than IPCW 
analyses because they do not account for all time- dependent 
confounding, but it was possible to incorporate more 
covariates in the two- stage models than the IPCW models 
in the METRIC analysis; hence, the IPCW may be more 
prone to unmeasured confounding. In particular, for the 
first- line treatment subgroup, we believe that the IPCW 
provided implausible results – the estimated HR appears 
unrealistically low. The IPCW method is prone to error 
in scenarios similar to those exhibited by the first- line 
subgroup within the METRIC trial – with very low num-
bers of control group patients not switching and potential 
unmeasured confounding [6, 23]. With the exception of 
this analysis, the complex adjustment methods provided 
reassuringly similar estimates of the true treatment effect 
of trametinib compared with chemotherapy on OS, sug-
gesting that the hazard of death is reduced by 47–52% 
in the primary efficacy population and 49–56% in the 
first- line subgroup, compared with ITT estimates of 28% 
and 33% in the primary efficacy population and first- line 
subgroups, respectively. Clinically, these results suggest 
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that the expected OS benefit associated with trametinib 
is substantially greater than that previously estimated using 
standard ITT analyses.
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